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Long-term treatment with the PARP inhibitor niraparib
does not increase the mutation load in cell line models
and tumour xenografts
Ádám Póti1, Kinga Berta1, Yonghong Xiao2, Orsolya Pipek3, Gregory T. Klus4,5,6, Thomas Ried4, István Csabai3, Keith Wilcoxen2,
Keith Mikule2, Zoltan Szallasi5,6,7,8 and Dávid Szüts 1
BACKGROUND: Poly-ADP ribose polymerase (PARP) inhibitor-based cancer therapy selectively targets cells with deﬁcient
homologous recombination repair. Considering their long-term use in maintenance treatment, any potential mutagenic effect of
PARP inhibitor treatment could accelerate the development of resistance or harm non-malignant somatic cells.
METHODS: We tested the mutagenicity of long-term treatment with the PARP inhibitor niraparib using whole-genome sequencing
of cultured cell clones and whole-exome sequencing of patient-derived breast cancer xenografts.
RESULTS: We observed no signiﬁcant increase in the number and alteration in the spectrum of base substitutions, short insertions
and deletions and genomic rearrangements upon niraparib treatment of human DLD-1 colon adenocarcinoma cells, wild-type and
BRCA1 mutant chicken DT40 lymphoblastoma cells and BRCA1-defective SUM149PT breast carcinoma cells, except for a minor
increase in speciﬁc deletion classes. We also did not detect any contribution of in vivo niraparib treatment to subclonal mutations
arising in breast cancer-derived xenografts.
CONCLUSIONS: The results suggest that long-term inhibition of DNA repair with PARP inhibitors has no or only limited mutagenic
effect. Mutagenesis due to prolonged use of PARP inhibitors in cancer treatment is therefore not expected to contribute to the
genetic evolution of resistance, generate signiﬁcant immunogenic neoepitopes or induce secondary malignancies.
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BACKGROUND
Cells with defective homologous recombination (HR) due to
mutation of the BRCA1 or BRCA2 genes are hypersensitive to the
inhibition of poly-ADP ribose polymerase-1 (PARP-1).1,2 This led
to the clinical development of PARP inhibitors as the ﬁrst class
of cancer therapeutics targeted against a DNA repair process.3
At the time of writing, three PARP inhibitor compounds are
approved for treating ovarian cancer. Olaparib was the ﬁrst
approved agent that received approval for the treatment of
germline BRCA-mutated advanced ovarian cancer that has
received three or more prior lines of chemotherapy. Rucaparib
was approved for the treatment of deleterious BRCA mutation
(germline and/or somatic)-associated advanced ovarian cancer
previously treated with two or more chemotherapies. More
recently, niraparib was approved for the maintenance treatment
of adult patients with recurrent epithelial ovarian, fallopian tube or
primary peritoneal cancer who are in complete or partial response
to platinum-based chemotherapy, without a restriction on germ-
line BRCA status. Further clinical trials are aimed at extending
the use of these drugs to breast cancer, prostate cancer and
pancreatic cancer, to test further PARP inhibitor compounds, and
to deﬁne patient pools that beneﬁt from PARP inhibitor treatment
in the absence of BRCA1/2 germline mutations.4–6 The use of
PARP inhibitors in a maintenance or adjuvant setting mandates
a careful assessment of any late-onset side effects.
The PARP-1 enzyme, the primary target of PARP inhibitors, is
involved in the repair of DNA single-strand breaks (SSBs). PARP
inhibitors prevent the repair of SSBs by trapping the inactivated
enzyme onto DNA, creating a block to replication and promoting
the collapse of replication forks at SSBs.7 A further DNA damage
tolerance function is attributed to PARP-1 in the rescue of stalled
replication forks,8,9 which may contribute to the mechanism of
synthetic lethality with BRCA1 and BRCA2. Niraparib inhibits both
PARP-1 and PARP-2 with low nanomolar half-maximal inhibitory
concentration (IC50) values, selectively kills BRCA1/2 mutant cancer
cells and traps PARP-1 more efﬁciently than olaparib.10,11
A potentially harmful side effect of the inhibition of DNA repair
as a therapeutic strategy is increased mutagenesis in the treated
cells. The genotoxic or mutagenic effect of PARP inhibition has
mainly been examined in BRCA1/2-deﬁcient cells, with reports of
increased chromosomal instability2,12,13 and increased mutagen-
esis in a hypoxanthine-guanine phosphoribosyltransferase (HPRT)
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reporter assay in BRCA2 mutant Capan-1 cells.12 In HR-proﬁcient
cells, PARP inhibition increases sister chromatid exchange (SCE)
formation and olaparib has also been shown to induce chromatid-
type chromosome aberrations.14,15
In contrast with the above ﬁndings, preclinical toxicology results
of clinically used PARP inhibitors reported no mutagenic effect in
the bacterial Ames test, while carcinogenicity was not investi-
gated. The Ames test is of limited relevance for this class of drugs,
as prokaryotes do not have PARP enzymes involved in DNA repair.
It was, therefore, important to obtain a comprehensive view of
genomic changes elicited by PARP inhibitors. Whole-genome
sequencing (WGS) of cultured cells following drug treatment
offers a convenient method for this purpose, which we success-
fully used to determine and compare the mutagenic effect of
several common anticancer cytotoxic agents, and demonstrate
the mutagenicity of cisplatin.16 In this study, we subjected BRCA
wild-type (WT) and BRCA mutant cell lines to long-term treatment
with the PARP inhibitor niraparib. WGS analysis of post-treatment
cell clones did not reveal increased mutagenesis, with subtle
exceptions. The lack of mutagenic effect was conﬁrmed in vivo
using patient-derived breast cancer xenograft (PDX) tumours.
METHODS
Cell culture
The following cell lines were used: WT and BRCA1−/− DT40 as used
previously,17 DLD-1 and 184B5 (ATCC) and SUM149PT (Asterand
Bioscience). All cell lines were tested for mycoplasma contamina-
tion, and validated using the WGS data obtained during this work.
DT40 cells were cultured in RPMI-1640 medium (Lonza) supple-
mented with 7% foetal bovine serum and 3% chicken serum; DLD-
1 and 184B5 cells were cultured in RPMI-1640 medium
supplemented with 10% foetal bovine serum; and
SUM149PT cells were cultured in Ham’s F12 medium (Sigma)
supplemented with 5% foetal bovine serum, 10 mM HEPES-NaOH
(pH 7.4), 1 μg/ml hydrocortisone and 5 μg/ml insulin (all from
Sigma). All cells were grown at 37 °C under 5% CO2.
PARP inhibitor treatments
Niraparib was obtained from Tesaro and dissolved in dimethyl
sulfoxide (DMSO) at 10 mM. Cytotoxicity assays were performed in
96-well cell culture plates. DT40 cells were plated at 5000 cells/
well, and niraparib was added at the time of plating. Measure-
ments were taken after 3 days on a Perkin-Elmer EnSpire
instrument, 2 h following the addition of 5% PrestoBlue reagent
(Thermo Fischer Scientiﬁc) to the medium. DLD-1 and
SUM149PT cells were plated at 1000 and 3000 cells/well,
respectively. The treatment was started one day after plating
(day 0), and the medium was changed on days 3 and 6 with
the inclusion of fresh niraparib. Measurements were taken on
day 8 as above, except that the growth medium was replaced
with phosphate-buffered saline containing 5% PrestoBlue. The
data were evaluated using GraphPad Prism.
Growth rates were calculated from daily cell counts. Long-term
niraparib treatments were performed over 30 days in 24-well cell
culture plates. Growth medium with or without freshly diluted
niraparib was replaced three times per week, and cells were
passaged two or three times per week as necessary. Cisplatin was
used at 10 μM for 1 h once a week for four cycles as described.16
Cells were cloned by limiting dilution. Genomic DNA preparations
were made from one to two million cells using the Gentra
Puregene method (Qiagen).
SCE assay
Niraparib and olaparib (Selleckchem) were added from 1mM
stock solutions in DMSO to produce a ﬁnal concentration of
500 nM and a ﬁnal DMSO concentration of 0.05%. SCE assays of
DLD-1 and 184B5 cells exposed to the various treatments were
performed essentially as described,18 with a 5-bromo-2′-deoxyur-
idine (BrdU) exposure duration of 43 and 40 h, respectively, and
with the BrdU exposure occurring at the same time as the
treatments. Modiﬁcations to the above protocol were (i) the use
of colcemid at 0.05 µg/ml for 90 min rather than at 0.02 µg/ml
for 4 h; (ii) the preparation of metaphase spreads by the method
described by Padilla-Nash et al.,19 with the spreading of the cells
on slides performed in a Cytogenetic Drying Chamber (Thermo-
tron, Holland, MI 49423 USA) at approximately 23 °C and with
the relative humidity of the chamber set at 47%.
PDX treatment
Outbred athymic (nu/nu) female mice (Hsd:Athymic Nude-
Foxn1nu) weighing 18–25 g (Harlan Laboratories, Gannat, France)
were subcutaneously implanted with HBCx xenografts. When
tumours reached a size of 70–200mm3, mice were assigned to
homogeneous groups of ﬁve animals and were dosed by oral
gavage daily at 50 mg/kg. A compound was prepared at least
48 h before administration by dissolution of powder by constant
stirring (and sonication when it was necessary) in 0.5%
methylcellulose at 10mg/ml. Tumours were collected 4 h after
the last dosing on day 28. Tumour volume was evaluated by
measuring biweekly tumour diameters with a caliper. The formula
tumour volume= (length x width2)/2 was used, where the length
and the width were the longest and the shortest diameters
of each tumour, respectively. Animals were euthanised if the
tumour volume exceeded 2000mm3. Extracted tumour samples
were formalin-ﬁxed and parafﬁn-embedded according to standard
methods.
DNA sequencing, mutation calling and data analysis
WGS was done at Novogene (Beijing, China). PDX sequencing was
done at BGI Americas (Cambridge, MA, USA). The alignment
of reads was done as described.17 The PDX-derived human and
mouse sequences were separated during the alignment process.
Independently arising SNVs and short indels were identiﬁed
using IsoMut,20 using default settings adjusted for copy number
for WGS, and the criteria of minimum three supporting reads and
exonic location for PDX mutations. Short deletions were classiﬁed
as repeat if the deleted sequence was present in at least two
tandem copies, and as microhomology if the sequence at the
two breakpoints contained at least one base pair of homology.
Structural variations were detected using CREST21 with post-
ﬁltering steps (Supplementary Methods).
Two-sided unpaired t tests were used for statistical comparisons
of mutation numbers with no adjustments for multiple
comparisons.
RESULTS
Modelling long-term PARP inhibitor treatment in cell lines
We modelled preclinical and clinical in vivo niraparib treatments in
cell lines by continuous exposure to niraparib for 30 days. To
avoid analysing non-independent cells derived from potential
drug-resistant subclones that may emerge during the treatment,
we isolated only a single-cell clone from each population for
analysis (Fig. 1a).
Four cell lines were selected for this study. Our earlier
demonstration of an in vitro reproduction of spontaneous and
BRCA defect-associated mutagenic processes observed in human
tumours17 provided the rationale to use an isogenic pair of WT
and BRCA1−/− mutant DT40 chicken lymphoblastoma cell lines for
the speciﬁc investigation of the effect of BRCA1 loss. A further
beneﬁt of using WT DT40 cells is their low spontaneous mutation
rate,16 which makes them a good model for mutagenesis in
somatic cells. We selected the DLD-1 human colorectal carcinoma
cell line for its normal karyotype and a high mutagenic rate due
to microsatellite instability,22 and the SUM149PT BRCA1 mutant
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triple-negative breast carcinoma cell line for highest relevance
to PARPI treatment and no detectable BRCA1 protein.23,24
Long-term niraparib treatment concentrations were established
using cytotoxicity assays. Niraparib selectively killed the BRCA1–/–
DT40 cells, with IC50 concentrations for the WT and the BRCA1
–/–
mutant measured as 369 nM (95% conﬁdence interval (CI):
154–796 nM) and 24 nM (95% CI: 11–51 nM), respectively (Fig. 1c).
DLD-1 was insensitive to niraparib treatment, with an IC50 in
excess of 4000 nM (Fig. 1d), and the BRCA1 mutant SUM149PT also
showed fairly low sensitivity despite the presence of the 2288delT
frameshift mutation, with an IC50 of 1841 nM (95% CI: 1426–2366
nM, Fig. 1e). We chose a treatment concentration of 500 nM for
the treatment of WT DT40, DLD-1 and SUM149PT cells, which is
around the peak plasma concentration measured in patients
receiving a daily oral dose of 300mg,25 and 50 nM for the DT40
BRCA1–/– cells. The treatments slightly slowed the growth of the
SUM149PT and DT40 BRCA1–/– lines (Fig. 1b), and appeared to lead
to reduced niraparib sensitivity in SUM149PT post-treatment cell
clones, but not in the other cell lines (Supplementary Fig. S1).
No signiﬁcant cell death was observed during the treatment,
suggesting that limited selection was involved in the isolation of
post-treatment clones.
Single-nucleotide variations in cell lines
Treatment-induced mutations were identiﬁed using the IsoMut
tool20 using separately optimised mutation ﬁlters for genomic
regions with distinct ploidy levels. We found that DT40 and
DLD-1 were largely diploid, whereas the SUM149PT cell line was
aneuploid, and most of the diploid regions showed loss of
heterozygosity (Supplementary Fig. S2).
Any difference in SNVs between the mock-treated and
niraparib-treated clones should show the mutagenic effect of
the drug. We identiﬁed 102 ± 29 (SD) spontaneous base
substitutions in mock-treated WT DT40 cells, not signiﬁcantly
different from 125 ± 11 SNVs found after niraparib treatment
(Fig. 2a and Table S1, p= 0.15, t test). The number of spontaneous
SNVs was about eight-fold higher in BRCA1−/− mutant cells
(849 ± 93) in agreement with our earlier results,17 and again similar
following niraparib treatment (Fig. 2a, b). The non-signiﬁcant 12%
decrease in the mean number of SNVs to 744 ± 31 (p= 0.077) may
be connected to the slower growth of the niraparib-treated cell
pools (Fig. 1b). DLD-1 cells showed a high level of spontaneous
SNV mutagenesis with 9799 ± 1910 genomic mutations acquired
over a 60-day culture period, which did not signiﬁcantly change
upon niraparib treatment (Fig. 2a and Table S1, p= 0.29). The
BRCA1mutant SUM149PT breast cancer cells had a lower mutation
rate with 608 ± 146 acquired base substitutions, which again
did not alter due to niraparib treatment (Fig. 2a and Table S1,
p= 0.56). In contrast, weekly repeated treatments with 10 μM
cisplatin were strongly mutagenic on WT DT40 cells (Supplemen-
tary Fig. S3), in agreement with our earlier results,16 and the
same treatment regimen also resulted in a signiﬁcant increase of
SNVs in the case of BRCA1−/− mutant cells (Supplementary Fig. S3,
p= 0.034, t test).
The triplet SNV spectra, showing each base substitution in
the context of the neighbouring bases, also did not reveal any
mutagenic effect of niraparib on either WT or BRCA1−/− mutant
DT40 cells (Fig. 2b–e and Supplementary Fig. S4). A visualisation
of the similarities of individual triplet spectra using t-distributed
stochastic neighbour embedding (t-SNE) clearly separates spectra
from different cell lines, but clusters the mock-treated and
niraparib-treated samples together, again indicating a lack of
mutagenic effect (Fig. 2f).
Our study also provides the ﬁrst characterisation of mutagenic
processes in the DLD-1 and SUM149PT cell lines. The comparison
of triplet SNV spectra with triplet mutation signatures derived
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Fig. 1 Long-term niraparib treatments. a A schematic outline of the long-term treatment experiments. Single-cell clones were expanded over
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from cancer genomes26,27 using t-SNE showed closest correlation
of the WT DT40 spontaneous spectrum with the ageing-associated
signature 1, whereas SNV mutagenesis in the DT40 BRCA1−/− cells
was best correlated with signature 3 typical of BRCA1/2 mutant
cancers (Fig. 2g) as published earlier.16,17 The calculation of
Pearson correlations or hierarchical clustering supports these
ﬁndings (Supplementary Fig. S5). In DLD-1 cells, the pattern of
spontaneous mutagenesis best correlated with signature 6,
followed by signatures 20 and 15 (Fig. 2g). These signatures were
found to associate with defective DNA mismatch repair (MMR),26
and the correlation is explained by the presence of frameshift
mutations in each allele of the key MMR gene MSH6 in the DLD-1
genome.22 Spontaneous SNV mutagenesis in the SUM149PT
cell line showed best correlation with signatures 4 and 8 (Fig. 2g
and Fig. S4). Unlike in the DT40 BRCA1−/− cells, mutagenesis
in the BRCA1 mutant SUM149PT cells showed only weak or no
correlation with the BRCA defect-associated signature 3. Therefore,
despite the presence of the homozygous 2288delT BRCA1
mutation, SUM149PT cells do not have a BRCA1-deﬁcient SNV
mutagenesis phenotype. Together with the low sensitivity to
niraparib, this suggests that suppressor mutations may have
arisen in the tumour or the cell line, but an analysis of the coding
mutations did not reveal any alterations in known HR-interacting
genes to explain the limited BRCA1-like phenotype of SUM149PT.
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Indels and large rearrangements in cell lines
We catalogued all short indels up to 50 bp, and found no
signiﬁcant difference in the number of insertions or deletions
between the mock-treated and niraparib-treated samples in the
investigated cell lines apart from a small but signiﬁcant increase in
the number of deletions in DT40 BRCA1−/− (Fig. 3a, b and
Table S1). We classiﬁed the deletions according to sequence
context. The high level of short deletions at repeat sequences in
the DLD-1 cell line conﬁrmed its microsatellite instability
phenotype (Fig. 3c). In the BRCA1−/− mutant DT40 cells, we found
more deletions of each category than in the WT, in agreement
with earlier results.17 In the BRCA1−/− cells we found a signiﬁcant
increase in events with one or more base pairs of microhomology
between the ends of the deletion upon niraparib treatment (p <
0.0001, t test), though there was no similar effect in the other cell
lines (Fig. 3c and Table S1). The increase in microhomology-
mediated deletions was speciﬁc to the BRCA1 mutant DT40 cells,
which might be due to an increased use of nonhomologous end
joining in the absence of HR at double-strand breaks resulting
from the collision of replication forks with trapped PARP enzymes.
There were few instances of larger insertions, deletions or
chromosomal rearrangements in the sequenced genomes. In
general, there was no signiﬁcant difference between the control
and the niraparib-treated samples, except for an increase in large
deletions in DLD-1 samples upon niraparib treatment (p= 0.038,
t test) (Fig. 4a).
SCEs are theoretically non-mutagenic rearrangements, and
the documented elevation of SCE numbers upon PARP inhibition
is likely due to increased HR providing a back-up for defective
SSB repair. We tested whether the treatment conditions used in
the in vitro experiments induce SCEs. Indeed, the treatment
of either DLD-1 cells or the 184B5 chemically immortalised non-
malignant breast epithelial cell line with 500 nM niraparib
or olaparib induced approximately four times more SCEs than
seen in the untreated controls (Fig. 4b, c). Contrasting the high
the rate of SCE formation at about 40/cell cycle in niraparib-
treated DLD-1 cells with the lack of observed SNV and indel
mutagenesis over approximately 30 cell divisions indicates
that the niraparib-induced formation of SCEs is essentially non-
mutagenic.
Niraparib treatment of breast cancer xenografts
To conﬁrm the cell line-derived results in vivo, we subjected mice
implanted with breast cancer-derived xenografts to 28 days of
niraparib treatment, and performed WGS on the extracted tumour.
Two BRCA1 WT PDX models were used, HBCx-31 derived from a
triple-negative invasive ductal carcinoma28 and the oestrogen-
dependent HBCx-34.29 Niraparib treatment slightly slowed the
growth of each PDX, but did not decrease their size (Fig. 5a, b).
Using IsoMut with permissive settings, we looked for subclonal
mutations unique to each tumour sample; as such mutations
would be expected to arise during the treatment. After careful
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separation of human and mouse sequences, we identiﬁed unique
SNVs and indels with low allele frequency in all samples (Fig. 5d, e).
There was no increase in the number of mutations or a change
in mutation spectra when comparing control and niraparib-
treated samples, indicating that niraparib treatment did not
generate detectable subclonal mutations in vivo (Fig. 5c, f, g). Note
that the spectrum of non-unique SNVs common to all samples of
each PDX is substantially different from the spectrum of unique
mutations (Fig. 5f–i), suggesting that the detection of unique
subclonal mutations was not contaminated by variations present
in the germline or the original tumour. The unique subclonal
mutations, therefore, indeed reﬂect ongoing mutagenesis speciﬁc
to the tumour, and could have reasonably been expected to
show any potential mutagenic effect of niraparib. The approach of
using high coverage WGS exome sequencing, necessary for the
detection of low allele frequency subclonal mutations, precludes
the analysis of subclonal structural variations in the investigated
tumour samples. The results from these BRCA1 WT PDX models
also serve to model mutagenesis in the somatic tissue of patients
with BRCA-deﬁcient tumours.
DISCUSSION
This work demonstrated that continuous treatment of various
cell lines and tumour xenografts with the PARP inhibitor
niraparib does not induce genomic SNV mutations, and also does
not induce small indels in BRCA-proﬁcient cells.
Genomic mutations can arise spontaneously during cell
proliferation, or due to exogenous sources. Of the four investi-
gated cell lines, WT DT40 has the lowest spontaneous mutation
rate, similar to the spontaneous mutation rates reported in a
number of organisms.16 The high sensitivity and speciﬁcity of the
employed mutation detection methods were demonstrated ear-
lier: with the IsoMut tool over 90% of SNVs and short indels can be
detected with a near-zero false-positive rate when multiple whole
genomes are analysed together.20 The assay was powered to
detect an approximately 25% increase over this background level,
but niraparib caused no signiﬁcant increase, suggesting that
clinical PARP inhibitor treatment could at most marginally increase
spontaneous rates of mutagenesis. While the spontaneous
mutation rates in the other cell lines were higher due to DNA
repair defects, the results support the same conclusion.
The spontaneous mutations were acquired over a period
encompassing over 100 cell divisions in DT40 cells, 50 cell division
in DLD-1 cells and about 30 cell divisions in the slow growing
SUM149PT cells. Somatic cells typically take years to go through
this number of divisions,30 and the correlation of cancer risk with
stem cell divisions suggests that mutations are mainly acquired
during active cell cycles,30 probably during DNA replication. With
the assumption that this would also apply to niraparib-induced
mutations, our experiments may have modelled years of
treatment. In contrast with the lack of mutagenesis upon niraparib
treatment, the same cell culture-based assay demonstrated a
high level of mutagenesis over the same period due to the
alkylating agents cisplatin, cyclophosphamide and methyl metha-
nesulfonate, and a low level following etoposide treatment.16,17
Moreover, our results showed an even stronger mutagenic effect
for cisplatin in BRCA1-deﬁcient cells. Currently, platinum agents
precede PARP inhibitors in the treatment of ovarian cancer,31 and
are also used to treat BRCA mutant triple-negative breast cancer.
Replacing platinum by non-mutagenic alternatives such as PARP
inhibitors will likely reduce the mutational load of tumour and
normal cells and thus reduce both the level of toxicity and the
incidence of secondary malignancies.
In preclinical models, PARP inhibitors showed synergistic
activity with immune checkpoint inhibitors,32 which has led to
several ongoing clinical trials combining these two promising new
classes of cancer therapeutic agents (see e.g. clinical trial
NCT02657889). Our results strongly suggest that this synergistic
effect is not due to the induction of neoepitopes by PARP
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inhibitors, but rather some other regulatory effect of immune
response relevant gene regulation.33
We found a signiﬁcant increase of microhomology-mediated
deletions in niraparib-treated BRCA1−/− DT40 cells. This effect
may be related to the HPRT mutagenesis seen in BRCA2 mutant
Capan-1 cells.12 If PARP inhibition has a weak selective mutagenic
effect on BRCA1/2-deﬁcient cells only, this may accelerate the
development of resistance in existing BRCA-deﬁcient tumours, but
would not contribute to the induction of secondary malignancies.
We did observe an induction of SCEs as also reported for olaparib
treatment,14,15 but this was not accompanied by mutagenesis.
Apart from an increase in the number of large deletions in DLD-1
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cells, we did not see an induction of chromosomal rearrange-
ments, which might be an expected consequence of chromosome
aberrations also reported for olaparib,14 but our assay here
was of limited power for these rare events due to the low
number of sequenced clones and the inability of the employed
CREST algorithm to detect rearrangements with unmappable
breakpoints.
A genetic loss of PARP-1 has been shown to accelerate the
induction of mammary tumours in mice.34 PARP-1 deletion is not
equivalent to inhibition by niraparib, which efﬁciently traps
the enzyme on DNA,10 but further experiments would be helpful
to test whether long-term in vivo PARP inhibitor treatment has
a detectable carcinogenic effect.
The results also have a direct relevance to the evolution
of resistance to PARP inhibitors. Two genetic mechanisms of
emerging PARP inhibitor resistance in HR-deﬁcient cells and
tumours have been documented in the literature: suppressor
mutations in genes such as 53BP135 and REV7,36 or secondary
mutations that restore the function of the originally mutated HR
genes such as BRCA1,37 BRCA2,38,39 RAD51C or RAD51D.40 We did
not observe the evolution of resistance by either mechanism,
though the large deletion in BRCA1 in DT40 cells precluded
genetic reversion. Importantly, mutagenic therapy can elicit
such reversion mutations, both in tumours and in vitro within
the 1-month timescale of cell culture model experiments.16,38
Our results suggest that unlike platinum agents, PARP inhibitor
treatment will not induce mutations responsible for treatment
resistance, and therefore the spontaneous mutagenic processes
of the tumour and the choice of additional therapeutic agents
will be most relevant to the rate of the evolution of PARP inhibitor
resistance.
In conclusion, our comprehensive results revealed no muta-
genic effect of niraparib apart from an increase in microhomology-
mediated deletions in BRCA1 mutant cells and an increase in large
deletions in one cell type. While the long-term clinical relevance
of such changes needs further study, our results suggest that
niraparib treatment is unlikely to have more than a minor
mutagenic effect on somatic and tumour cells.
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